Beta Bionics (NASDAQ:BBNX) Insider Steven Jon Russell Sells 4,222 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Steven Jon Russell sold 4,222 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the transaction, the insider owned 173,849 shares in the company, valued at $2,192,235.89. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Price Performance

Shares of BBNX opened at $12.45 on Thursday. The company has a market capitalization of $554.59 million, a price-to-earnings ratio of -8.24 and a beta of 3.40. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The business’s 50-day moving average is $10.83 and its 200-day moving average is $17.31.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. Equities research analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on BBNX. Leerink Partners lowered their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Lake Street Capital set a $20.00 price target on Beta Bionics in a research note on Wednesday, February 18th. The Goldman Sachs Group lowered their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Robert W. Baird lowered their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Finally, Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.70.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics said it is now publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support investor confidence in the company’s commercial progress and transparency. Article Title
• Neutral Sentiment: Several top executives disclosed stock sales on June 2, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger. Each sale was relatively small and was stated to be for tax withholding related to vesting equity awards, which makes the transactions less concerning than open-market selling, but the volume may still weigh on sentiment.
• Negative Sentiment: Multiple law firms, including Robbins LLP and Johnson Fistel, announced investigations into Beta Bionics and its officers/directors over possible securities-law violations and investor losses. These headlines suggest litigation risk and can spark concerns about disclosure practices and governance. Article Title
• Negative Sentiment: A shareholder alert said Robbins LLP is investigating whether Beta Bionics executives and directors violated securities laws and breached fiduciary duties, adding to the legal overhang. Article Title
• Negative Sentiment: Johnson Fistel also said it is investigating whether investors suffered losses after Beta Bionics reported slower new patient start growth, highlighting concerns that growth momentum may be decelerating. Article Title

Institutional Investors Weigh In On Beta Bionics

A number of large investors have recently added to or reduced their stakes in BBNX. Vanguard Group Inc. boosted its position in Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after purchasing an additional 1,509,217 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Beta Bionics during the fourth quarter worth approximately $40,437,000. Eversept Partners LP boosted its position in Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. 12 West Capital Management LP bought a new stake in Beta Bionics during the fourth quarter worth approximately $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in Beta Bionics during the first quarter worth approximately $5,518,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.